Sakar Healthcare Ltd

As of March 31, 2026, Sakar Healthcare Ltd carries a market capitalization of 11.09B, placing it among publicly traded companies globally. Its enterprise value stands at 11.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Sakar Healthcare Ltd has 22.25M shares outstanding.

As of March 31, 2026, Sakar Healthcare Ltd trades at a trailing price-to-earnings ratio of 36.40. The price-to-sales ratio is 4.41, and the price-to-book ratio stands at 3.42.

As of March 31, 2026, Sakar Healthcare Ltd trades at an EV/EBITDA multiple of 17.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 11.79B versus a market cap of 11.09B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Sakar Healthcare Ltd maintains a current ratio of 1.28, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.74, indicating elevated leverage, while an interest coverage ratio of 8.77 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Sakar Healthcare Ltd posted a return on equity (ROE) of 10.00, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.84 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.80, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.52, useful for judging operating efficiency across full business cycles. The company generates approximately 7.36M in revenue per employee across its workforce of 342.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.17 indicates how many times Sakar Healthcare Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Sakar Healthcare Ltd recorded 92.71M in income tax expense. That works out to an effective tax rate of 23.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 397.55M, leaving 304.85M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Sakar Healthcare Ltd's stock has gained approximately 160.87% over the past 52 weeks. The 50-day moving average sits at 1,012.32, while the 200-day moving average is 728.65.

Over the twelve months ended March 31, 2026, Sakar Healthcare Ltd generated 2.52B in revenue and converted that into 304.85M in net income, yielding earnings per share of 13.69. EBITDA reached 688.88M, while operating income came in at 453.24M.

As of March 31, 2026, Sakar Healthcare Ltd holds 2.60M in cash and equivalents against 705.34M in total debt, resulting in a net debt position of 704.92M. Total book value stands at 3.24B, with working capital of 309.21M providing operational flexibility.

Over the twelve months ended March 31, 2026, Sakar Healthcare Ltd posted a gross margin of 51.03, reflecting its pricing power and cost economics. The operating margin of 18.00 and net profit margin of 12.11 provide insight into operational efficiency.

As of March 31, 2026, Sakar Healthcare Ltd has an Altman Z-Score of 5.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.